The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.50
Bid: 52.00
Ask: 53.00
Change: 0.20 (0.38%)
Spread: 1.00 (1.923%)
Open: 52.00
High: 53.20
Low: 53.20
Prev. Close: 53.00
CLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Calnex receives two Queen’s awards for Enterprise

21 Apr 2022 07:00

RNS Number : 8046I
Calnex Solutions PLC
21 April 2022
 

RNS Reach

21 April 2022

 

Calnex Solutions plc

("Calnex", the "Company" or the "Group")

Calnex Solutions receives two Queen's awards for Enterprise in Innovation and International Trade

 

Calnex Solutions plc (AIM: CLX), a leading provider of test and measurement solutions for the global telecommunications sector, today announces it has been honoured with two Queen's Awards for Enterprise in recognition of its outstanding contribution to Innovation and International Trade as the Group continues to develop a world leading range of test and measurement solutions for the global telecommunications sector.

 

Calnex is one of only seven companies in the UK to be recognised with two Queen's Awards for Enterprise in 2022. This is the second time Calnex has been awarded the UK's highest accolade for business success, after winning the Queen's Award for Enterprise for International Trade in 2015, acknowledging the Company's global reputation for innovative products and sales achievements.

 

Now in its 56th year, the Queen's Awards for Enterprise are the UK's most prestigious business awards to recognise and encourage achievements in the fields of Innovation, International Trade, Sustainable Development and Promoting Opportunity through social mobility.

 

Employing 122 people, and founded in 2006, Calnex designs and produces test instrumentation for network synchronisation, enabling its customers to validate the performance of the critical infrastructure associated with telecoms networks. Calnex now has over 600 customer sites in 68 countries across the world and customers include the likes of BT, Qualcomm, IBM and Facebook. Calnex completed its successful IPO on the AIM market of the London Stock Exchange in October 2020, providing the Group with the funds to invest in its continued success as the Company seeks to capitalise on the long-term transition of the telecoms market to 5G and the growth of cloud computing.

 

Commenting on the award, CEO Tommy Cook, said:

"We are honoured to receive two such prestigious awards, in Innovation and International Trade, and Calnex is proud to be representing Scottish innovation globally. The significance of the Queen's Award is known worldwide and being awarded this accolade twice in one year is an indication of the good progress we have made over the past few years. During this time we have successfully become a public company and continued to invest in the growth of the Company and the development of our team and these awards are a testament to the dedication and expertise of our staff and quality of our expanding offering. Britain has always been at the forefront of innovation across the telecommunications sector and these awards further validate our leading position in the marketplace."

 

For more information, please contact:

Calnex Solutions plc

Via Alma PR

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

 

 

 

Cenkos Securities plc - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

 

 

Alma PR

+ 44(0) 20 3405 0213

Caroline Forde, Hannah Campbell, Joe Pederzolli

 

 

Overview of Calnex

Calnex designs, produces and markets test instrumentation and solutions for network synchronization and network emulation, enabling its customers to validate the performance of the critical infrastructure associated with telecoms networks. To date, Calnex has secured and delivered orders to over 600 customer sites in 68 countries across the world. Customers include BT, China Mobile, NTT, Ericsson, Nokia, Intel, Qualcomm, IBM and Meta.

Founded in 2006, Calnex is headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland and California in the US, supported by sales teams in China and India. Calnex has a global network of partners, providing a worldwide distribution capability. 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAKLEAEEAEFA
Date   Source Headline
10th Apr 20247:00 amRNSNotice of Investor Presentation
3rd Apr 20247:00 amRNSFY24 Trading Update and Notice of Results
21st Feb 20249:28 amRNSExercise of Options
14th Feb 20241:08 pmRNSExercise of Options
12th Dec 20233:47 pmRNSPDMR Dealings
21st Nov 20237:00 amRNSInterim Results
1st Nov 202312:24 pmRNSChange of Nominated Adviser
26th Oct 20237:00 amRNSNotice of Investor Presentation
10th Oct 20233:17 pmRNSTrading Update and Notice of Results
25th Aug 20234:36 pmRNSPDMR Dealings
16th Aug 20231:22 pmRNSResult of AGM
16th Aug 20237:00 amRNSAGM Statement
11th Aug 20232:00 pmRNSLong-Term Incentive Plan Awards
17th Jul 20237:00 amRNSNotice of AGM
12th Jul 202312:05 pmRNSDirector/PDMR Dealings
12th Jun 20234:34 pmRNSPDMR Dealings
23rd May 20237:00 amRNSFY23 Final Results
11th May 20239:00 amRNSPDMR Dealings
4th May 20237:00 amRNSNotice of Results and Investor Presentation
14th Apr 20236:03 pmRNSPDMR Dealings
14th Apr 20233:24 pmRNSDirector Dealing
15th Mar 20231:15 pmRNSDirector Dealings
14th Mar 20234:00 pmRNSPDMR Dealings
7th Mar 20239:05 amRNSSecond Price Monitoring Extn
7th Mar 20239:00 amRNSPrice Monitoring Extension
7th Mar 20237:00 amRNSTrading Update
15th Feb 202310:59 amRNSPDMR Dealings
19th Jan 20239:56 amRNSPDMR Dealings
17th Jan 20239:56 amRNSDirector / PDMR Dealings
17th Jan 20239:52 amRNSHolding(s) in Company
17th Jan 20237:00 amRNSBoard Changes
13th Jan 20234:00 pmRNSDirector/PDMR Dealing
13th Dec 20222:15 pmRNSDirector / PDMR Dealings
22nd Nov 20227:00 amRNSInterim Results
21st Nov 20225:43 pmRNSDirector / PDMR Dealings
27th Oct 20227:00 amRNSNotice of Results and Investor Presentation
14th Oct 20223:53 pmRNSDirector/PDMR Shareholding
12th Oct 20221:29 pmRNSDirector / PDMR Dealings
15th Sep 20227:30 amRNSDirector/PDMR Dealing
17th Aug 20225:26 pmRNSResult of AGM
17th Aug 20227:00 amRNSAGM Statement
15th Aug 202210:26 amRNSDirector / PDMR Dealings
26th Jul 20223:33 pmRNSDirector / PDMR Shareholding
18th Jul 20227:00 amRNSNotice of AGM
14th Jul 20225:49 pmRNSDirector/PDMR Dealings
8th Jul 20226:01 pmRNSDirector / PDMR dealings
15th Jun 20227:00 amRNSExercise of Options
14th Jun 20227:00 amRNSBoard Update
6th Jun 20221:30 pmRNSDirector Dealing
24th May 20227:00 amRNSFY22 Final Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.